Company delivers 9% revenue growth, record revenue from high-value solutions, expanded margins, and maintains fiscal year 2025 guidance
PIOMBINO DESE, Italy--(BUSINESS WIRE)--November 06, 2025--
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2025.
Third Quarter 2025 Highlights (comparisons to prior-year period)
-- Revenue increased 9% (11% on a constant currency basis) to EUR303.2
million.
-- High-value solutions represented a record 49% of total revenue.
-- Gross profit margin increased 240 basis points to 29.2%.
-- Diluted earnings per share were EUR0.13; adjusted diluted earnings per
share were EUR0.14.
-- Adjusted EBITDA margin increased 280 basis points to 25.7%.
-- The Company is maintaining its fiscal 2025 guidance and continues to
expect revenue in the range of EUR1.160 billion to EUR1.190 billion,
adjusted EBITDA in the range of EUR288.5 million to EUR301.8 million, and
adjusted diluted EPS in the range of EUR0.50 to EUR0.54.
Third Quarter 2025 Results
For the third quarter of 2025, revenue increased 9% year-over-year (11% on a constant currency basis) to EUR303.2 million, driven by a 14% (17% on a constant currency basis) revenue increase from the Company's Biopharmaceutical and Diagnostic Solutions (BDS) Segment, which offset the anticipated revenue decline from the Engineering Segment.
Third quarter financial results benefited from the favorable timing of product shipments of approximately EUR10 million in the BDS Segment that were previously forecasted to occur in the fourth quarter of 2025. Compared with the same period last year, third quarter results also reflect the absorption of the unfavorable impact from foreign currency translation and certain tariff costs that were not mitigated and were already assumed in the Company's guidance.
Revenue from high-value solutions increased 47%, year-over-year, to a record EUR147.9 million, representing 49% of total revenue for the third quarter of 2025. This growth was driven primarily by robust demand for high-performance Nexa$(R)$ syringes, and to a lesser extent, EZ-fill(R) vials.
In the third quarter of 2025, strong performance in the BDS Segment led to a 240 basis-point increase in gross profit margin to 29.2%, compared with the same period last year, driven by: (i) the favorable mix of high-value solutions, (ii) the expected financial improvements at the Latina and Fishers manufacturing facilities as volumes and revenue scale, and (iii) the ongoing recovery in vial demand. These positive trends were offset by the lower gross profit margin from the Engineering Segment, the impact from foreign currency translation, and certain tariff costs that were not mitigated.
As a result, operating profit margin for the third quarter of 2025 increased 260 basis points, compared with the same period last year, to 17.4%, while adjusted operating profit margin rose 220 basis points, compared with the same period last year, to 18.5%, driven predominantly by an increase in gross profit. This was partially offset by higher operating expenses in the Engineering Segment for research and development activities associated with the Company's next generation RTU 400 EZ-fill(R) cartridge lines.
For the third quarter of 2025, net profit was EUR36.1 million, with diluted earnings per share of EUR0.13, and on an adjusted basis, net profit was EUR38.5 million with diluted earnings per share of EUR0.14. For the third quarter of 2025, adjusted EBITDA increased to EUR77.8 million and the adjusted EBITDA margin improved 280 basis points to 25.7%, compared with the same period last year.
Franco Stevanato, Chairman and Chief Executive Officer, stated, "We delivered a solid third quarter with 9% revenue growth and a record 47% increase in high-value solutions, driven primarily by demand for high-performance Nexa(R) syringes. Financial results were better-than-expected due to the timing of product shipments that were previously expected to occur in the fourth quarter, and we remain on track to achieve our fiscal 2025 guidance. Our strategic investments in capacity expansion and innovation position us to meet rising demand for injectable biologics, biosimilars, and ready-to-use platforms, to support our customers with patient-centric solutions."
Biopharmaceutical and Diagnostic Solutions (BDS) Segment
Revenue grew 14% (17% on a constant currency basis) to EUR266.7 million for the third quarter of 2025, compared with the same period last year, driven by a 47% increase from high-value solutions. The Segment benefited from favorable timing of product shipments of approximately EUR10 million that were previously forecasted to occur in the fourth quarter of 2025.
Revenue from high-value solutions increased to a record EUR147.9 million and represented 55% of BDS Segment revenue in the third quarter, led by strong growth in high-performance Nexa(R) syringes and, to a lesser extent, EZ-fill(R) vials. Growth continues to be fueled by the expanding production capacity for high-value syringes, as the Latina and Fishers manufacturing facilities scale operations to meet increasing demand. Revenue from other containment and delivery solutions decreased 10% to EUR118.8 million, compared with the same period last year. This was driven by a decline in revenue from low-value syringes and in-vitro diagnostics, as the Company transitions to a larger portfolio of high-value projects, and was partially offset by growth in bulk vials and contract manufacturing activities.
For the third quarter of 2025, gross profit margin increased 400 basis points to 32.0% and operating profit margin rose by 520 basis points to 22.1%, compared with the same period last year, driven by: (i) the favorable mix of high-value solutions, (ii) the financial improvements from the new facilities in Latina and Fishers as they gain scale, and (iii) an increase in vial demand as the effects of destocking continue to abate. This was partially offset by the unfavorable effects from foreign currency translation and certain tariff costs that were not mitigated.
Engineering Segment
As expected, revenue from the Engineering Segment decreased 19% to EUR36.4 million for the third quarter of 2025, compared with the same period last year, driven by lower revenue from glass converting and assembly lines, which was partially offset by growth in pharma inspection and after-sales activities.
For the third quarter of 2025, gross profit margin for the Engineering Segment decreased 520 basis points to 10.4%, compared with the same period last year, and continued to be impacted by an unfavorable project mix that reflected a higher proportion of complex legacy projects in Denmark and a lower volume of new work.
Balance Sheet and Cash Flow
As of September 30, 2025, the Company had cash and cash equivalents of EUR113.3 million and net debt of EUR333 million.
Capital expenditures totaled EUR54.9 million for the third quarter of 2025, as the Company continues to ramp-up capacity in its new manufacturing facilities in response to customer demand for high-value solutions.
In the third quarter of 2025, cash flow from operating activities was EUR47.2 million. Cash flow used for the purchase of property, plant, and equipment, and intangible assets totaled EUR48.4 million. Strong operational cash flow and reduced capital expenditures resulted in EUR0.3 million in free cash flow for the third quarter of 2025, and EUR16.9 million for the nine-months ended September 30, 2025.
The Company believes that it has adequate liquidity to fund its strategic priorities over the next twelve months through a combination of cash on hand, cash generated from operations, available credit lines, and the ability to access additional financing.
2025 Guidance
The Company is maintaining its fiscal 2025 guidance and continues to expect:
-- Revenue in the range of EUR1.160 billion to EUR1.190 billion; -- Adjusted EBITDA in the range of EUR288.5 million to EUR301.8 million; and -- Adjusted diluted EPS in the range of EUR0.50 to EUR0.54.
Franco Stevanato concluded, "Our performance underscores the strength of our long-term strategy and business fundamentals. The strategic investments we've made, the innovation we've delivered, and the trust we've built with our customers are the foundation of the strong momentum we're carrying into fiscal 2026. With a healthy pipeline, favorable market dynamics, and a clear strategic focus, we are well-positioned to drive growth, improve patient outcomes, and deliver lasting value for our customers, employees, and shareholders."
Conference call: The Company will host a conference call and webcast at 8:30 a.m. $(ET)$ on Thursday, November 6, 2025, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Investor Relations section of the Company's website.
Pre-registration: Participants who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. We encourage participants to pre-register for the conference call using the following link: Pre-registration for STVN Q3 2025 earnings webcast.
Webcast: A live, listen-only webcast of the call will be available at the following link: STVN Q3 2025 webcast.
Dial in: Those who are unable to pre-register may dial in by calling:
Italy: +39 02 802 09 11
United Kingdom: +44 1 212 818004
United States: +1 718 705 8796
United States Toll Free: +1 855 265 6958
Questions during the call: Participants who wish to ask questions during the call should use the HD webphone link: STVN Q3 2025 Link for Questions
Replay: The webcast will be archived for three months on the Company's Investor Relations section of its website.
Forward-Looking Statements
This press release may include forward-looking statements. The words "maintaining," "continues," "expect," "remain," "position," "rising," "expanding," "scale," "well-positioned," "drive," "improve," "deliver," "increasing," "continue," "believes," and other similar expressions (or their negative) identify certain of these forward-looking statements. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's future financial performance, including revenue, operating expenses and ability to maintain profitability, and operational and commercial capabilities; the Company's expectations regarding the development of the industry and the competitive environment in which it operates; the expansion of the Company's plants and sites, and our expectations related to our capacity expansion; the global supply chain and the Company's committed orders; customer demand; the success of the Company's initiatives to optimize the industrial footprint, harmonize processes and enhance supply chain and logistics strategies; the Company's geographical and industrial footprint; and the Company's goals, strategies, and investment plans. The forward-looking statements in this press release are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future, and may cause the actual results, performance, or achievements of the Company to be materially different from those expressed or implied by such forward looking statements. Many of these risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely, such as conditions in the U.S. capital markets, negative global and domestic economic and political conditions, inflation, trade war and global tariff policies, the impact of the conflict between Russia and the Ukraine, the evolving events in Israel and Gaza, supply chain and logistical challenges and other factors such as the Company's ability to continue to obtain financing to meet its liquidity needs, changes in the geopolitical, social and regulatory framework in which the Company operates or in economic or technological trends or conditions. For a description of the risks that could cause the Company's future results to differ from those expressed in any such forward looking statements, refer to the risk factors discussed in our most recent annual report on Form 20-F filed on March 6, 2025, and our most recent filings with the U.S. Securities and Exchange Commission. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Except as required by law, the Company assumes no obligation to update any such forward-looking statements.
Non-GAAP Financial Information
This press release contains non-GAAP financial measures. Please refer to the tables included in this press release for a reconciliation of non-GAAP financial measures.
Management monitors and evaluates our operating and financial performance using several non-GAAP financial measures, including Constant Currency Revenue, EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Operating Profit, Adjusted Operating Profit Margin, Adjusted Income Taxes, Adjusted Net Profit, Adjusted Diluted EPS, CAPEX, Free Cash Flow, Net Cash/(Debt), and Capital Employed. The Company believes that these non-GAAP financial measures provide useful and relevant information regarding its performance and improve its ability to assess our financial condition. While similar measures are widely used in the industry in which the Company operates, the financial measures it uses may not be comparable to other similarly titled measures used by other companies, nor are they intended to be substitutes for measures of financial performance or financial position as prepared in accordance with IFRS.
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group's core capabilities in scientific research and development, its commitment to technical innovation, and its engineering excellence are central to its ability to offer value added solutions to clients. To learn more, visit: www.stevanatogroup.com.
Consolidated Income Statement
(Amounts in EUR millions, except per share data)
For the three months For the nine months
ended September 30, ended September 30,
2025 % 2024 % 2025 % 2024 %
Revenue 303.2 100.0% 277.9 100.0% 839.8 100.0% 773.4 100.0%
Costs of sales 214.7 70.8% 203.4 73.2% 602.8 71.8% 569.3 73.6%
----- ----- ----- ----- ----- ----- ----- -----
Gross Profit 88.5 29.2% 74.4 26.8% 237.0 28.2% 204.2 26.4%
Other operating
Income 2.7 0.9% 1.3 0.5% 4.8 0.6% 3.6 0.5%
Selling and
Marketing
Expenses 7.1 2.3% 5.8 2.1% 20.3 2.4% 19.0 2.5%
Research and
Development
Expenses 7.6 2.5% 6.6 2.4% 19.6 2.3% 26.1 3.4%
General and
Administrative
Expenses 23.8 7.8% 22.3 8.0% 73.1 8.7% 68.4 8.8%
----- ----- ----- ----- ----- ----- ----- -----
Operating Profit 52.7 17.4% 41.0 14.8% 128.7 15.3% 94.3 12.2%
Finance Income 0.5 0.2% 2.1 0.8% 13.9 1.7% 8.2 1.1%
Finance Expense 4.1 1.3% 2.4 0.9% 19.3 2.3% 6.8 0.9%
----- ----- ----- ----- ----- ----- ----- -----
Profit Before Tax 49.1 16.2% 40.8 14.7% 123.3 14.7% 95.6 12.4%
Income Taxes 13.1 4.3% 10.8 3.9% 31.1 3.7% 26.2 3.4%
----- ----- ----- ----- ----- ----- ----- -----
Net Profit 36.1 11.9% 30.0 10.8% 92.3 11.0% 69.4 9.0%
Earnings per
share
Basic earnings
per ordinary
share 0.13 0.11 0.34 0.26
Diluted earnings
per ordinary
share 0.13 0.11 0.34 0.26
Average shares
outstanding 273.0 272.9 272.9 270.5
Average shares
assuming
dilution 273.0 272.9 272.9 270.6
Reported Segment Information
(Amounts in EUR millions)
For the three months ended September 30, 2025
Adjustments,
eliminations
Biopharmaceutical and
and Diagnostic unallocated
Solutions Engineering items Consolidated
------------------ ----------- ------------- ------------
External
Customers 266.7 36.4 -- 303.2
Inter-Segment 0.7 26.9 (27.6) --
----------------- ----------- ------------- ------------
Revenue 267.5 63.3 (27.6) 303.2
----------------- ----------- ------------- ------------
Gross Profit 85.7 6.6 (3.8) 88.5
----------------- ----------- ------------- ------------
Gross Profit
Margin 32.0% 10.4% 29.2%
----------------- ----------- ------------- ------------
Operating Profit 59.0 (0.7) (5.6) 52.7
----------------- ----------- ------------- ------------
Operating Profit
Margin 22.1% (1.1)% 17.4%
----------------- ----------- ------------- ------------
For the three months ended September 30, 2024
Adjustments,
eliminations
Biopharmaceutical and
and Diagnostic unallocated
Solutions Engineering items Consolidated
------------------ ----------- ------------- ------------
External
Customers 233.0 44.8 -- 277.9
Inter-Segment 1.8 48.6 (50.4) --
----------------- ----------- ------------- ------------
Revenue 234.9 93.4 (50.4) 277.9
----------------- ----------- ------------- ------------
Gross Profit 65.9 14.6 (6.0) 74.4
----------------- ----------- ------------- ------------
Gross Profit
Margin 28.0% 15.6% 26.8%
----------------- ----------- ------------- ------------
Operating Profit 39.7 9.5 (8.1) 41.0
----------------- ----------- ------------- ------------
Operating Profit
Margin 16.9% 10.1% 14.8%
----------------- ----------- ------------- ------------
For the nine months ended September 30, 2025
Adjustments,
eliminations
Biopharmaceutical and
and Diagnostic unallocated
Solutions Engineering items Consolidated
------------------ ----------- ------------ ------------
External
Customers 731.1 108.7 -- 839.8
Inter-Segment 2.0 97.0 (99.0) --
----------------- ----------- ------------ ------------
Revenue 733.1 205.7 (99.0) 839.8
----------------- ----------- ------------ ------------
Gross Profit 231.2 19.1 (13.3) 237.0
----------------- ----------- ------------ ------------
Gross Profit
Margin 31.5% 9.3% 28.2%
----------------- ----------- ------------ ------------
Operating Profit 147.3 2.5 (21.1) 128.7
----------------- ----------- ------------ ------------
Operating Profit
Margin 20.1% 1.2% 15.3%
----------------- ----------- ------------ ------------
For the nine months ended September 30, 2024
Adjustments,
eliminations
Biopharmaceutical and
and Diagnostic unallocated
Solutions Engineering items Consolidated
------------------ ----------- ------------ ------------
External
Customers 654.3 119.1 -- 773.4
Inter-Segment 3.0 131.2 (134.2) --
----------------- ----------- ------------ ------------
Revenue 657.3 250.3 (134.2) 773.4
----------------- ----------- ------------ ------------
Gross Profit 181.6 36.2 (13.7) 204.2
----------------- ----------- ------------ ------------
Gross Profit
Margin 27.6% 14.5% 26.4%
----------------- ----------- ------------ ------------
Operating Profit 100.2 16.7 (22.6) 94.3
----------------- ----------- ------------ ------------
Operating Profit
Margin 15.2% 6.7% 12.2%
----------------- ----------- ------------ ------------
Cash Flow
(Amounts in EUR millions)
For the three For the nine
months ended months ended
September 30, September 30,
2025 2024 2025 2024
------ --------- ------ ---------
Cash flow from
operating
activities 47.2 18.3 192.0 112.1
Cash flow used
in investing
activities (48.2) (47.6) (178.6) (219.2)
Cash flow from
financing
activities 19.4 29.4 4.9 116.9
----- --------- ------ ---------
Net change in
cash and cash
equivalents 18.4 0.1 18.3 9.9
----- --------- ------ ---------
Non-GAAP Financial Information
This press release contains non-GAAP financial measures. Please refer to "Non-GAAP Financial Information" and the tables included in this press release for a reconciliation of non-GAAP financial measures.
Reconciliation of Revenue to Constant Currency Revenue
(Amounts in EUR millions)
Biopharmaceutical
and
Three months ended Diagnostic
September 30, 2025 Solutions Engineering Consolidated
Reported Revenue
(IFRS GAAP) 266.7 36.4 303.2
Effect of changes
in currency
translation
rates 5.4 -- 5.4
----------------- ----------- ------------
Constant Currency
Revenue (Non-IFRS
GAAP) 272.2 36.4 308.6
----------------- ----------- ------------
Biopharmaceutical
and
Nine months ended Diagnostic
September 30, 2025 Solutions Engineering Consolidated
Reported Revenue
(IFRS GAAP) 731.1 108.7 839.8
Effect of changes
in currency
translation
rates 9.7 -- 9.7
----------------- ----------- ------------
Constant Currency
Revenue (Non-IFRS
GAAP) 740.8 108.7 849.5
----------------- ----------- ------------
Reconciliation of EBITDA
(Amounts in EUR millions)
For the three For the nine
months ended months ended
September 30, Change September 30, Change
2025 2024 % 2025 2024 %
---------------- ----- -------- ------ ----- --------- ------
Net Profit 36.1 30.0 20.1% 92.3 69.4 32.9%
Income Taxes 13.1 10.8 21.3% 31.1 26.2 18.7%
Finance Income (0.5) (2.1) (78.2)% (13.9) (8.2) 69.9%
Finance
Expenses 4.1 2.4 71.1% 19.3 6.8 182.0%
---- -------- ------ ----- --------- ------
Operating
Profit 52.7 41.0 28.5% 128.7 94.3 36.5%
Depreciation
and
Amortization
and Impairment
of PPE 21.8 18.4 18.1% 64.0 60.9 5.0%
---- -------- ------ ----- --------- ------
EBITDA 74.5 59.5 25.3% 192.7 155.2 24.1%
---- -------- ------ ----- --------- ------
Calculation of Net Profit Margin, Operating Profit Margin, Adjusted EBITDA
Margin and Adjusted Operating Profit Margin
(Amounts in EUR millions)
For the nine months
For the three months ended September
ended September 30, 30,
2025 2024 2025 2024
------------------------- ------ -------- ----- --------
Revenue 303.2 277.9 839.8 773.4
Net Profit Margin (Net
Profit/ Revenue) 11.9% 10.8% 11.0% 9.0%
Operating Profit Margin
(Operating Profit/
Revenue) 17.4% 14.8% 15.3% 12.2%
Adjusted EBITDA Margin
(Adjusted EBITDA/
Revenue) 25.7% 22.9% 23.8% 21.8%
Adjusted Operating
Profit Margin (Adjusted
Operating Profit/
Revenue) 18.5% 16.3% 16.2% 13.9%
Reconciliation of Reported and Adjusted EBITDA, Operating Profit, Income
Taxes,
Net Profit, and Diluted EPS
(Amounts in EUR millions, except per share data)
Three months Income Diluted EPS
ended September Operating Taxes Net (EUR
30, 2025 EBITDA Profit (4) Profit cents)
----------------- ------- ---------- ------ ------ -----------
Reported 74.5 52.7 13.1 36.1 0.13
Adjusting
items:
Start-up costs
new plants (1) 2.4 2.4 0.7 1.8 0.01
Restructuring
and related
charges (2) 0.9 0.9 0.2 0.7 0.00
------ ---------- ------ ------ -----------
Adjusted 77.8 56.1 14.0 38.5 0.14
------ ---------- ------ ------ -----------
Adjusted Margin 25.7% 18.5%
Three months Income Diluted EPS
ended September Operating Taxes Net (EUR
30, 2024 EBITDA Profit (4) Profit cents)
----------------- ------- --------- ------ ------ -----------
Reported 59.5 41.0 10.8 30.0 0.11
Adjusting
items:
Start-up costs
new plants (1) 3.5 3.5 1.0 2.6 0.01
Restructuring
and related
charges (2) 0.5 0.5 0.1 0.4 0.00
Other severance
costs (3) 0.2 0.2 0.1 0.2 0.00
------ --------- ------ ------ -----------
Adjusted 63.7 45.2 11.9 33.1 0.12
------ --------- ------ ------ -----------
Adjusted Margin 22.9% 16.3%
Nine months ended Income Diluted EPS
September 30, Operating Taxes Net (EUR
2025 EBITDA Profit (4) Profit cents)
----------------- ------- --------- ------ ------ -----------
Reported 192.7 128.7 31.1 92.3 0.34
Adjusting
items:
Start-up costs
new plants (1) 4.5 4.5 1.2 3.3 0.01
Restructuring
and related
charges (2) 3.1 3.1 0.8 2.3 0.01
------ --------- ------ ------ -----------
Adjusted 200.3 136.3 33.0 97.9 0.36
------ --------- ------ ------ -----------
Adjusted Margin 23.8% 16.2%
Nine months ended Income Diluted EPS
September 30, Operating Taxes Net (EUR
2024 EBITDA Profit (4) Profit cents)
----------------- ------- --------- ------ ------ -----------
Reported 155.2 94.3 26.2 69.4 0.26
Adjusting
items:
Start-up costs
new plants (1) 9.2 9.2 2.5 6.7 0.02
Restructuring
and related
charges (2) 3.6 3.6 0.9 2.7 0.01
Other severance
costs (3) 0.2 0.2 0.1 0.2 0.00
------ --------- ------ ------ -----------
Adjusted 168.3 107.3 29.6 79.1 0.29
------ --------- ------ ------ -----------
Adjusted Margin 21.8% 13.9%
(1) During the three and the nine months ended September 30, 2025, and the
Group recorded EUR 2.4 million and EUR 4.5 million, respectively, of start-up
costs for the new plants in Fishers, Indiana, United States, and in Latina,
Italy. These costs are primarily related to labor costs for training and
travel of personnel who are in the learning and development phase and not
active in the manufacturing of products. During the three and the nine months
ended September 30, 2024, the Group recorded EUR 3.5 million and EUR 9.2
million, respectively, of start-up costs for the new plants in Fishers,
Indiana, United States, and in Latina, Italy.
(2) During the three and the nine months ended September 30, 2025, the Group
recorded EUR 0.9 million and EUR 3.1 million, respectively, of restructuring
and related charges among cost of sales, selling and marketing and general and
administrative expenses. These are mainly employee costs related to the
reorganization of some business functions. During the three and the nine
months ended September 30, 2024, the Group recorded EUR 0.5 million and EUR
3.6 million, respectively, of restructuring and related charges among general
and administrative expenses and research and development expenses.
(3) During the three and the nine months ended September 30, 2024, the Group
recorded EUR 0.2 million related to personnel expenses, including other
severance costs.
(4) The income tax adjustment is calculated by multiplying the applicable
nominal tax rate to the adjusting items.
Capital Employed
(Amounts in EUR millions)
As of
September 30, As of December
2025 31, 2024
------------------------------ --------------- --------------
- Goodwill and intangible
assets 83.5 83.6
- Right of use assets 12.9 15.7
- Property, plant, and
equipment 1,317.3 1,248.4
- Financial assets -
investments FVTPL 0.1 0.2
- Other non-current
financial assets 13.2 5.4
- Deferred tax assets 102.4 95.3
-------------------------------- -------------- --------------
Non-current assets excluding
FV of derivative financial
instruments 1,529.4 1,448.7
-------------------------------- -------------- --------------
- Inventories 274.7 245.2
- Contract assets 182.7 168.5
- Trade receivables 266.8 296.0
- Trade payables (210.4) (231.0)
- Advances from customers (38.0) (16.6)
- Non-current advances
from customers (63.2) (44.0)
- Contract liabilities (8.0) (16.5)
-------------------------------- -------------- --------------
Trade working capital 404.6 401.6
-------------------------------- -------------- --------------
- Tax receivables and
other receivables 39.2 70.6
- Current financial
receivables - rent to
buy agreement 0.9 --
- Non-current assets held
for sale -- 0.2
- Tax payables and other
current liabilities (120.9) (92.2)
- Current provisions (4.9) (4.1)
-------------------------------- -------------- --------------
Net working capital 318.9 376.1
-------------------------------- -------------- --------------
- Deferred tax liabilities (13.3) (12.6)
- Employees benefits (6.7) (7.2)
- Non-current provisions (2.9) (2.8)
- Other non-current
liabilities (55.2) (62.7)
-------------------------------- -------------- --------------
Total non-current liabilities
and provisions (78.0) (85.3)
-------------------------------- -------------- --------------
Capital employed 1,770.3 1,739.4
-------------------------------- -------------- --------------
Net (debt) /cash (333.0) (335.0)
-------------------------------- -------------- --------------
Total Equity (1,437.3) (1,404.4)
-------------------------------- -------------- --------------
Total equity and net (debt)/
cash (1,770.3) (1,739.4)
-------------------------------- -------------- --------------
Free Cash Flow
(Amounts in EUR millions)
For the three For the nine
months ended months ended
September 30, September 30,
2025 2024 2025 2024
------ --------- ------ ---------
Net cash flow
from
operating
activities 47.2 18.3 192.0 112.1
Interest paid 1.4 1.5 4.9 3.8
Interest
received (0.2) (0.5) (1.2) (1.7)
Purchase of
property,
plant, and
equipment (46.4) (44.6) (174.4) (213.7)
Proceeds from
sale of
property,
plant, and
equipment 0.2 0.1 1.6 3.1
Purchase of
intangible
assets (2.0) (3.2) (6.0) (8.7)
----- --------- ------ ---------
Free Cash
Flow 0.3 (28.4) 16.9 (105.0)
----- --------- ------ ---------
Net (Debt) / Net Cash
(Amounts in EUR millions)
As of As of December
(MORE TO FOLLOW) Dow Jones Newswires
November 06, 2025 06:30 ET (11:30 GMT)
Comments